• Glaukos raised 2026 net sales guidance to $775 million-$785 million from $680 million-$700 million.
• Preliminary 2027 revenue guidance reached $1 billion, factoring in potential restrictive Medicare coverage decisions for iDose TR.
• Third-quarter net sales rose 58% to a record $211 million.
• Epioxa contributed approximately $53 million in sales; iDose TR generated approximately $76 million.
• The October 28, 2026 earnings call featured CEO Thomas William Burns, COO Joseph E. Gilliam and CFO Alex R. Thurman.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.